| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA984: Tafamidis for treating transthyretin amyloidosis with cardiomyopathy |
|
Medicine details |
|
| Medicine name | tafamidis (Vyndaqel®) |
| Formulation | 20 mg capsule |
| Reference number | 2441 |
| Indication | Treatment of treatment of wild‑type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) |
| Company | Pfizer Ltd |
| BNF chapter | Cardiovascular system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 09/01/2020 |
| NICE guidance | TA984: Tafamidis for treating transthyretin amyloidosis with cardiomyopathy |